Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Treatment with immune checkpoint blockade (CPB) therapies often leads to prolonged responses in patients with metastatic melanoma, but the common mechanisms of primary and acquired resistance to these agents remain incompletely characterized and have yet to be validated in large cohorts. By analyzin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Sade-Feldman, Moshe, Jiao, Yunxin J., Chen, Jonathan H., Rooney, Michael S., Barzily-Rokni, Michal, Eliane, Jean-Pierre, Bjorgaard, Stacey L., Hammond, Marc R., Vitzthum, Hans, Blackmon, Shauna M., Frederick, Dennie T., Hazar-Rethinam, Mehlika, Nadres, Brandon A., Van Seventer, Emily E., Shukla, Sachet A., Yizhak, Keren, Ray, John P., Rosebrock, Daniel, Livitz, Dimitri, Adalsteinsson, Viktor, Getz, Gad, Duncan, Lyn M., Li, Bo, Corcoran, Ryan B., Lawrence, Donald P., Stemmer-Rachamimov, Anat, Boland, Genevieve M., Landau, Dan A., Flaherty, Keith T., Sullivan, Ryan J., Hacohen, Nir
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5656607/
https://ncbi.nlm.nih.gov/pubmed/29070816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-017-01062-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados